Project Details
Description
HM2024-18 A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis
| Status | Active |
|---|---|
| Effective start/end date | 7/10/24 → 7/9/35 |
Funding
- SUMITOMO PHARMA AMERICA, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.